Celltrion Pharm Stock Total Debt
| 068760 Stock | KRW 52,700 300.00 0.57% |
Celltrion Pharm fundamentals help investors to digest information that contributes to Celltrion Pharm's financial success or failures. It also enables traders to predict the movement of Celltrion Stock. The fundamental analysis module provides a way to measure Celltrion Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celltrion Pharm stock.
Celltrion |
Celltrion Pharm Company Total Debt Analysis
Celltrion Pharm's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Celltrion Pharm Total Debt | 39.4 B |
Most of Celltrion Pharm's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celltrion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Celltrion Pharm has a Total Debt of 39.4 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all Republic of Korea stocks is notably lower than that of the firm.
Celltrion Pharm is the top company in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 78.8 Billion. Celltrion Pharm totals roughly 39.4 Billion in total debt claiming about 50% of equities under Health Care industry.Celltrion Fundamentals
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 34.05 M | |||
| Shares Owned By Insiders | 57.79 % | |||
| Shares Owned By Institutions | 6.75 % | |||
| Price To Earning | 62.82 X | |||
| Price To Sales | 8.22 X | |||
| Revenue | 398.74 B | |||
| Gross Profit | 72.93 B | |||
| EBITDA | 42.8 B | |||
| Net Income | 34.58 B | |||
| Cash And Equivalents | 80.19 B | |||
| Cash Per Share | 815.33 X | |||
| Total Debt | 39.4 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.25 X | |||
| Book Value Per Share | 10,914 X | |||
| Cash Flow From Operations | 93.15 B | |||
| Target Price | 136000.0 | |||
| Number Of Employees | 29 | |||
| Beta | 0.23 | |||
| Market Capitalization | 2.1 T | |||
| Total Asset | 637.88 B | |||
| Retained Earnings | 30.6 B | |||
| Working Capital | 58.94 B | |||
| Current Asset | 144.21 B | |||
| Current Liabilities | 85.27 B | |||
| Z Score | 31.8 | |||
| Net Asset | 637.88 B |
About Celltrion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.